Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study. (PubMed, Diabetes Obes Metab) - Sep 28, 2026 - "In this real-world CKD cohort, GLP-1RA added to SGLT2i therapy was associated with substantial incremental reductions in kidney disease progression and cardiovascular events. These findings suggest an additive cardiorenal benefit, particularly in patients with obesity, supporting the evaluation of combination therapy in future randomised trials."
Journal • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Genetic Disorders • Heart Failure • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Retinal Disorders
|
|
Amit Garg; Gaurav S Gulsin; Gerry P McCann; Habib R Khan; Hussain Salim; Kamlesh Khunti; Mohammed Shurrab; Muhammad Rashid; Saad Ahmed Waqas; Shaheer Qureshi
|